Glazer Capital LLC’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Glazer Capital LLC’s Portfolio EUCRU Stock Details EUCRU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,502	Closed	-$85K	–	614
2022 Q3	$85K	Buy	8,502 +2,800	+49%	+$27.9K	﹤0.01%	564
2022 Q2	$56K	Buy	5,702 +2,692	+89%	+$26.7K	﹤0.01%	572
2022 Q1	$30K	Buy	+3,010	New	+$29.9K	﹤0.01%	468
2021 Q4	–	Sell	-79,779	Closed	-$791K	–	972
2021 Q3	$791K	Hold	79,779	–	–	0.01%	492
2021 Q2	$814K	Sell	79,779 -2,600	-3%	-$26.1K	0.01%	538
2021 Q1	$829K	Sell	82,379 -143,306	-63%	-$1.53M	0.01%	530
2020 Q4	$2.41M	Buy	+225,685	New	+$2.29M	0.09%	205

Other funds holding EUCRU

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Glazer Capital LLC's EUCRU Position: Q4 2022 in Review

Glazer Capital LLC sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q4 2022, closing a stake of 8,502 shares — an estimated $85K sold.

Glazer Capital LLC first reported a position in EUCRU in Q4 2020 and held it in 7 quarters. The position peaked at $2.41M in Q4 2020. 6 funds tracked by Wall St. Rank hold EUCRU as of Q4 2022.

Glazer Capital LLC reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
Glazer Capital LLC sold 8,502 Eucrates Biomedical Acquisition Corp. Unit shares in Q4 2022, an estimated $85K.
Glazer Capital LLC first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 7 quarters.
Glazer Capital LLC's Eucrates Biomedical Acquisition Corp. Unit position peaked at $2.41M in Q4 2020.
6 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q4 2022.

Based on Glazer Capital LLC's 13F filing for Q4 2022, filed 14 Feb 2023.